Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P25445

UPID:
TNR6_HUMAN

ALTERNATIVE NAMES:
Apo-1 antigen; Apoptosis-mediating surface antigen FAS; FASLG receptor

ALTERNATIVE UPACC:
P25445; A9UJX4; B6VNV4; Q14292; Q14293; Q14294; Q14295; Q16652; Q5T9P1; Q5T9P2; Q5T9P3; Q6SSE9

BACKGROUND:
The protein known as Apoptosis-mediating surface antigen FAS, or simply FAS, is integral to apoptosis and immune regulation. By binding to its ligand TNFSF6/FASLG, FAS triggers a cascade of caspases that lead to cell death, playing a key role in eliminating autoreactive lymphocytes and maintaining immune balance.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Autoimmune lymphoproliferative syndrome 1A, FAS represents a significant target for therapeutic intervention. Exploring FAS's function could unveil new strategies for treating autoimmune and hematological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.